Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Valneva For 2024 Expects Total Revenues Of €170M-€190M And R&D Investments Between €60M-€75M

Author: Benzinga Newsdesk | May 07, 2024 01:47am

2024 financial guidance confirmed

  • Expected total revenues between €170 million and €190 million, including:
    • €160 million to €180 million of sales driven by growth of Valneva's proprietary products
  • Expected R&D investments between €60 million and €75 million, mostly dedicated to ongoing chikungunya development activities, the Zika trial and advancement of pre-clinical programs
  • Expected Other income between €100 million and €110 million, reflecting €95 million in proceeds from the PRV sale

Posted In: VALN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist